Sonrotoclax

Sonrotoclax, sold under the brand name Beqalzi, is a medication used for the treatment of hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).[1] It is a potent and selective BCL2 inhibitor that can overcome resistance associated with BCL2 mutations, such as the G101V variant, which limits the effectiveness of first-generation inhibitors like venetoclax.[2]

## Contents

* 1 Medical uses
* 2 Contraindications
* 3 Society and culture
* 3.1 Legal status
* 3.2 Names
* 4 References

## Medical uses

Sonrotoclax is indicated for the treatment of adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor.[3]

## Contraindications

Sonrotoclax is contraindicated with strong CYP3A inhibitors at initiation and ramp-up phase due to potential increased risk of Tumor lysis syndrome.[3]

## Society and culture

### Legal status

Sonrotoclax was approved by the FDA for medical use in the United States in May 2026.[3] Sonrotoclax is also approved in China for mantle cell lymphoma, along with CLL/SLL.[3]

Sonrotoclax also has a fast track designation by the FDA for Waldenström macroglobulinemia. It additionally has an orphan drug designation by the FDA for Waldenström macroglobulinemia, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndromes.[3]

### Names

Sonrotoclax is the international nonproprietary name.[4]

Sonrotoclax is sold under the brand name Beqalzi.[3]

## References

1. ↑ "Sonrotoclax - BeiGene". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800056704.
2. ↑ "Review of BCL2 inhibitors for the treatment of Waldenström's macroglobulinaemia and non-IgM lymphoplasmacytic lymphoma". Frontiers in Oncology 14. 2024. doi:10.3389/fonc.2024.1490202. PMID 39558954.
3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 "BeOne Medicines' Beqalzi (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma" (Press release). Beone Medicines. 13 May 2026. Retrieved 23 May 2026 - via Business Wire.
4. ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 90". WHO Drug Information 37 (3). 2023.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Sonrotoclax. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Sonrotoclax&oldid=4434002"